PULMONARY HYPERTENSION (WORLD HEALTH ORGANIZATION GROUP 2)

Clinical trials for PULMONARY HYPERTENSION (WORLD HEALTH ORGANIZATION GROUP 2) explained in plain language.

Never miss a new study

Get alerted when new PULMONARY HYPERTENSION (WORLD HEALTH ORGANIZATION GROUP 2) trials appear

Sign up with your email to follow new studies for PULMONARY HYPERTENSION (WORLD HEALTH ORGANIZATION GROUP 2), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New injection aims to ease strain on failing hearts and lungs

Disease control Completed

This study tested whether a new injectable drug, AZD3427, could reduce high blood pressure in the lungs of people who also have heart failure. About 260 participants received either the drug or a placebo injection every two weeks for 24 weeks. The main goal was to see if the drug…

Matched conditions: PULMONARY HYPERTENSION (WORLD HEALTH ORGANIZATION GROUP 2)

Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Mar 27, 2026 12:40 UTC

PULMONARY HYPERTENSION (WORLD HEALTH ORGANIZATION GROUP 2)

Get alerted when new PULMONARY HYPERTENSION (WORLD HEALTH ORGANIZATION GROUP 2) trials appear

New injection aims to ease strain on failing hearts and lungs